Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine:: better antibody increase from booster dose of the Edmonston-Zagreb vaccine
Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine:: better antibody increase from booster dose of the Edmonston-Zagreb vaccine
复制标题
DOI：
10.1016/s0264-410x(00)00431-x
复制
发表时间：
2001-02-28
期刊：
影响因子：
5.5
通讯作者：
Whittle, HC
中科院分区：
文献类型：
--
作者：
Garly, ML;Balé, C;Whittle, HC
在几内亚比绍，儿童在 6 个月大时被随机分配，分别在 6 个月和 9 个月大时接受两剂标准滴度麻疹疫苗，或在 6 个月大时接受灭活脊髓灰质炎疫苗，并在 9 个月大时接受标准滴度麻疹疫苗。在前 5 个月内，儿童接种了埃德蒙斯顿-萨格勒布 (EZ) 疫苗，并在接下来的 11 个月内接种了施瓦茨 (SW) 疫苗。 5% 的母亲、74% 6 个月大的儿童和 92% 92% 未接种疫苗的 9 个月大儿童的麻疹抗体水平处于非保护水平 (< 125 mIU/ml)。在接受 EZ 疫苗的儿童中，1% 的儿童在接种两剂 (3/240) 或一剂 (3/211) 疫苗后在 18 个月时未受到保护，两组的几何平均麻疹抗体滴度 (GMT) 均为 1550 mIU/ml。在接受 SW 疫苗的儿童中，两剂组和一剂组中分别有 9% (34/365) 和 3% (9/310) 在 18 月龄时未受到保护（RR = 3.21（95% 置信区间 (CI) 1.56-6.58））。 9 月龄时接种一剂 SW 疫苗后的 GMT (2491 mIU/ml) 高于接种两剂 SW 疫苗后的 GMT (1125 mIU) (P < 0.001)。在EZ疫苗组中，在母体抗体水平高或低的情况下接种疫苗的儿童的抗体水平没有显着差异，而SW组则存在显着差异。第二剂 EZ 疫苗在 9 个月龄（1191 mIU）和 11 月龄（1602 mIU，P = 0.011）之间诱导抗体显着增加，而在第二剂 SW 疫苗后，抗体水平从 9 个月（1243 mIU）到 18 个月龄（998 mIU，P = 0.124）趋于下降。总之，与接种两剂 SW 疫苗相比，接种两剂 EZ 麻疹疫苗后，更多的儿童在 18 个月大时受到保护。一剂 SW 提供最高的抗体反应，但未受保护的比例高于一剂或两剂 EZ。 EZ 疫苗对母体抗体不太敏感，并且能够通过重新接种来增加抗体反应，而第二种 SW 疫苗则导致抗体反应不变或较低。 (C) 2001 Elsevier Science Ltd. 保留所有权利。
In Guinea-Bissau, children were randomised at 6 months of age to receive either two doses of standard-titre measles vaccine at 6 and 9 months of age or an inactivated polio vaccine at 6 months and standard-titre measles vaccine at 9 months of age. During the first 5 months, children received Edmonston-Zagreb (EZ) vaccine and during the following 11 months, the Schwarz (SW) vaccine. Five percent of the mothers, 74% of children at 6 months of age, and 92% of unvaccinated children at 9 months of age had unprotective levels ( < 125 mIU/ml) of measles antibodies. Among children receiving EZ vaccine, 1%, were unprotected at 18 months of age after either two (3/240) or one (3/211) doses of vaccine, the geometric mean measles antibody titre (GMT) being 1550 mIU/ml in both groups. Among those receiving SW vaccine 9% (34/365) and 3% (9/310) were unprotected at 18 months of age in the two-dose and the one-dose groups (RR = 3.21 (95% confidence interval (CI) 1.56-6.58)), respectively. The GMT was higher after one dose of SW vaccine at 9 months of age (2491 mIU/ml) than after two doses of SW vaccine (1125 mIU) (P < 0.001). In the EZ vaccine group, there was no significant difference in antibody level for children vaccinated in the presence of high or low levels of maternal antibodies, whereas there was a marked difference in the SW group. The second EZ vaccine induced a significant antibody increase between 9 months of age (1191 mIU) and Is months of age (1602 mIU, P = 0.011), whereas antibody levels tended to decline from 9 months (1243 mIU) to 18 months of age (998 mIU, P = 0.124) after the second dose of SW vaccine. Conclusively, after two doses of EZ measles vaccine more children were protected at 18 months of age than after two doses of SW. One dose of SW provided the highest antibody response, but a higher proportion of unprotected than one or two doses of EZ. The EZ vaccine was less sensitive to maternal antibodies, and able to increase the antibody response by revaccination, while the second SW vaccine resulted in an unchanged or lower antibody response. (C) 2001 Elsevier Science Ltd. All rights reserved.